Not provided
Not provided
Not provided
Not provided
Not provided
We recruited a target number (740 patients) earlier than the expected day of copletion
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study (Statin Eligibility Prior to myocardial infarction (MI) in Jordanians, StatinEPIC) is
Statins, when use as primary cardiovascular prevention strategy, have been shown to lower future acute cardiovascular events, especially myocardial infarction. However the use of statins in this context (i.e., primary prevention) is governed by guidelines that limit the use of statins to four high risk populations: (1) hose with known cardiovascular disease, (2) those with low-density lipoprotein cholesterol (LDL-C) levels 190 mg/dl or above, (3) diabetics with LDL-C levels 70-189 mg/dl, and (4) those with an estimated 10-year atherosclerotic cardiovascular disease risk score of 7.5% or more.
Unfortunately, some individuals are still at risk of sustaining MI despite the fact that they do not fit into one of these four high risk groups eligible for statins.
StainEPIC will enroll consecutive patients admitted with MI who are not on statins to examine their eligibility for these medications based on the AHA/ACC guidelines.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| No intervention | Other | No intervention. Collection of data on statin eligibility in patients admitted with MI |
| Measure | Description | Time Frame |
|---|---|---|
| Eligible patients for statin therapy | The primary outcome is to calculate the percentage of enrolled patients who do meet the AHA/ACC Guidelines for receiving statins as a primary prevention measure. | Within 24 hour of enrollment |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Male, female
Patients aged 30 to 75 years admitted with MI (ST elevation and non ST elevation) who are not receiving statins prior to admission will be evaluated for potential eligibility had they been evaluated prior to admission with MI.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Yasmine Obeidat, MS | Hashemmeyyeh University School of Medicine, Zarka, Jordan | Study Director |
| Ayman J Hammoudeh, MD, FACC | Istishari Hospital, Department of Cardiology, Amman, Jordan | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Istishari Hospital | Amman | 11184 | Jordan | |||
| The University of Jordan |
All IPD files will be available for all study researchers: clinical data, lipid profile data, 10 year risk score data, statin eligibility data.
Not provided
Not provided
Not provided
Not provided
| Type | Date | Date Unknown |
|---|---|---|
| Release | Apr 29, 2020 | |
| Reset | May 8, 2020 | |
| Release | May 11, 2020 | |
| Reset | May 20, 2020 | |
| Release | Jan 29, 2024 | |
| Reset | Jul 12, 2024 | |
| Release | Feb 23, 2025 | |
| Reset | Mar 13, 2025 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Apr 29, 2020 | May 8, 2020 | |||
| May 11, 2020 |
| ID | Term |
|---|---|
| D009203 | Myocardial Infarction |
| ID | Term |
|---|---|
| D017202 | Myocardial Ischemia |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D014652 | Vascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| Amman |
| 11942 |
| Jordan |
| Jordan Hospital | Amman | Jordan |
| Khalidi Hospital & Medical Center | Amman | Jordan |
| King Abdullah University Hospital | Irbid | Jordan |
| May 20, 2020 |
| Jan 29, 2024 | Jul 12, 2024 |
| Feb 23, 2025 | Mar 13, 2025 |
| D007238 |
| Infarction |
| D007511 | Ischemia |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D009336 | Necrosis |